“…GSK-3 inhibitors are widely used as therapeutic agents against diabetes (Castro and Martinez, 2000), stroke, cancer, and other maladies (Hoeflich et al, 2000). Thus, the synthesis and prediction of novel GSK-3 inhibitors has been subject of a variety of studies (Engler et al, 2005;Cross et al, 2001;Hers et al, 1999;Kuo et al, 2003;Leost et al, 2000;Meijer et al, 2000;Meijer et al, 2003;Peat et al, 2004;Ring et al, 2003;Tavares et al, 2004). recently designed a series of GSK-3 ligands using a de novo approach, whose docking methodology was calibrated using a series of reference compounds.…”